The association between tocilizumab and the secondary bloodstream infection maybe nonsignificant in hospitalized patients with SARS-CoV-2 infection: A cohort study

Background: Immunomodulatory agents, such as tocilizumab (TCZ), exert promising effects against SARS-CoV-2 infection. However, growing evidence indicates that using TCZ may carry higher risks of secondary bloodstream infection (sBSI). This study determined whether TCZ is associated with an increased...

Full description

Bibliographic Details

Published in:	Journal of Microbiology, Immunology and Infection
Main Authors:	De-En Lu, Tsong-Yih Ou, Jyun-Wei Kang, Jie Ywi Ong, I-Ju Chen, Chih-Hsin Lee, Ming-Chia Lee
Format:	Article
Language:	English
Published:	Elsevier 2024-02-01
Subjects:	SARS-CoV-2 infection Secondary bloodstream infections Tocilizumab
Online Access:	http://www.sciencedirect.com/science/article/pii/S1684118223002025